Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM082 in wAMD
NCT02452385Phase 1Suspended
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Mar 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorolanib in exudative macular degeneration, sponsored by AnewPharma Company, Ltd. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 6 months. Started Mar 2015; status: suspended.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02452385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452385.